Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.

Mutant KRAS is a major driver of oncogenesis in a multitude of cancers but remains a challenging target for classical small molecule drugs, motivating the exploration of alternative approaches. Here, we show that aggregation-prone regions (APRs) in the primary sequence of the oncoprotein constitute...

ver descrição completa

Detalhes bibliográficos
Autores: Janssen, Kobe, Claes, Filip, Van de Velde, Dido, Wehbi, Vanessa L, Houben, Bert, Lampi, Yulia, Nys, Mieke, Khodaparast, Laleh, Khodaparast, Ladan, Louros, Nikolaos, van der Kant, Rob, Verniers, Joffre, Garcia, Teresa, Ramakers, Meine, Konstantoulea, Katerina, Maragkou, Katerina, Duran-Romaña, Ramon, Musteanu, Mónica, Barbacid, Mariano, Scorneaux, Bernard, Beirnaert, Els, Schymkowitz, Joost, Rousseau, Frederic
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26789
Acesso em linha:https://hdl.handle.net/20.500.12105/26789
Access Level:acceso abierto
Palavra-chave:KRAS
oncogene
peptide
protein aggregation
protein folding
Descrição
Resumo:Mutant KRAS is a major driver of oncogenesis in a multitude of cancers but remains a challenging target for classical small molecule drugs, motivating the exploration of alternative approaches. Here, we show that aggregation-prone regions (APRs) in the primary sequence of the oncoprotein constitute intrinsic vulnerabilities that can be exploited to misfold KRAS into protein aggregates. Conveniently, this propensity that is present in wild-type KRAS is increased in the common oncogenic mutations at positions 12 and 13. We show that synthetic peptides (Pept-ins™) derived from two distinct KRAS APRs could induce the misfolding and subsequent loss of function of oncogenic KRAS, both of recombinantly produced protein in solution, during cell-free translation and in cancer cells. The Pept-ins exerted antiproliferative activity against a range of mutant KRAS cell lines and abrogated tumor growth in a syngeneic lung adenocarcinoma mouse model driven by mutant KRAS G12V. These findings provide proof-of-concept that the intrinsic misfolding propensity of the KRAS oncoprotein can be exploited to cause its functional inactivation.

Registos relacionados